Twenty-year Follow-up of the Inter99 Cohort
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 4,000
- 试验地点
- 1
- 主要终点
- Major adverse cardiovascular events (MACE) (Register data)
研究概览
简要总结
Being born small increases your risk of developing Type 2 diabetes (T2D) with age. Furthermore, data even suggest that some of the diseases ("complications") in the eyes, kidneys, nerves, liver, blood vessels and heart often seen in T2D patients may not only be due to high blood sugar levels, but rather they to some extent are due to reduced growth in your mother´s womb. The Inter99 cohort included 6784 Danish citizens aged 30 to 60 years when established 20 years ago. Data from the Inter99 cohort showed a strong role of low birth weight (LBW) on T2D risk. The aim is now to reexamine risk of T2D and complications in all the alive 6004 elderly Inter99 participants. Importantly, today there are available techniques to perform detailed examinations for even the earliest signs of complications in both subjects with and without diabetes, and the results of this study will altogether provide important new insights into both the origin and classification of T2D and associated complications. It is hypothesized that being born with lower birth weights increases the adult risk of T2D and heart disease and associated complications in the large and smaller blood vessels.
详细描述
BACKGROUND Type 2 Diabetes (T2D) affecting globally more than 400 million people represents one of the most significant global health challenges of our time. However, despite huge research investments, there are still limited insights into its complicated etiology and pathophysiology during the life-course. T2D is furthermore defined by arbitrary glycemic thresholds, which inadequately captures the diversity of clinical presentations and sub-phenotypes with differential complications and damages in multiple organs including small and large vessels, heart, kidney, liver and nerve tissue, often present already at the time of disease onset.
The heterogeneity of phenotypes in T2D is likely rooted in differential genetic, prenatal, and postnatal non-genetic etiologies between individuals. As for genetics, the known 568 T2D susceptibility variants are estimated to account for 18% of the putative genetic contribution to T2D. The totality of data from human famine catastrophes conclusively confirm the initial reports from Hertfordshire, UK, of an adverse intrauterine environment associated with low birth weight (LBW) playing a significant role in the development of T2D. The concept of fetal and early life developmental programming has been confirmed, validated and mechanistically examined in multiple animal studies. Studies in humans and animals have provided compelling evidence of an adverse fetal environment contributing to virtually all the known multiple organ defects influencing glucose homeostasis. Furthermore, emerging evidence consistently suggest that LBW and an adverse fetal environment play a direct and independent role in the development of important complications in T2D including cardiovascular disease, hypertension, dyslipidemia and vascular dysfunctions. Vascular stiffness reflected by elevated pulse-wave-velocity are early signs of micro- and/or macrovascular disease in patients with and without T2D. The fact that T2D patients often have a significant burden of vascular and metabolic complications already at diagnosis, indicates that factors influencing risk of T2D at the same time represent direct causes of co-morbidities that it is otherwise considered as complications to hyperglycemia. Accordingly, a distinct subgroup of T2D patients, as a result of an adverse fetal environment, may be affected by diabetic complications to a larger extent than patients with T2D due to other factors. Indeed, it was reported that LBW accounts for most of the excess cardiovascular disease (CVD) mortality in T2D. Moreover, LBW is associated with smaller kidneys with fewer nephrons and increased risk of chronic kidney disease. Another study reported increased risk of cardiac autonomic function (heart rate variability) in children, which is a known risk factor of CVD morbidity and mortality. Patients with T2D are at increased risk of developing NAFLD, which may progress to non-alcoholic stereo hepatitis (NASH), overt liver cirrhosis and liver cancer. NAFLD and NASH are clinically silent and under-diagnosed diseases with a global prevalence of 25-30% and is associated with increased risk of CVD in a non-genetic manner. Recent unpublished data from our group showed a threefold increased liver fat content in young, non-diabetic LBW men when studied before and after 4 weeks of a high carbohydrate challenge diet.
AIM To give a detailed phenotypical cardiometabolic description of the population-based Inter99-cohort, in order to examine associations of size at birth and prematurity, as proxies for the early fetal environment, concurrent lifestyle factors and genetic risk with the age-specific incidence of T2D and CVD, and its complications and co-morbidities, among Danish citizens aged 50-80 years.
HYPOTHESIS
- An adverse fetal environment (LBW and/or prematurity) is associated with increased risk of developing a more severe T2D sub-phenotype with increased morbidity and mortality from micro- and macro vascular complications as well as cardiometabolic co-morbidities including NAFLD, compared with T2D patients born at term with a normal birth weight.
- An adverse fetal environment is associated with increased morbidity and mortality from a range of micro- and macrovascular manifestations, as well as NAFLD, typically referred to as diabetes complications, even among elderly non- diabetic people with or without prediabetes (impaired glucose tolerance or impaired fasting glucose).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 82 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have participated in the Inter99 Baseline examination.
排除标准
- •Physically or cognitively unable to participate in the 3-hour clinical follow-up study.
结局指标
主要结局
Major adverse cardiovascular events (MACE) (Register data)
时间窗: As data are collected from registers, the events are registered as they occur up until 1 Jan 2020.
Composite endpoint of cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke (3 points MACE). Data are retrieved from the Danish national registers as described in the "study population" section.
次要结局
- Diabetic retinopathy (Optos)(Measured one time during the clinical follow-up study (Day 1).)
- Handgrip strength (Handgrip dynamometer)(Assessed in each participant at the clinical follow-up (Day 1).)
- Type 2 diabetes incidence (register data)(As data are collected from registers, the events are registered as they occur up until 1 Jan 2020.)
- Hypertension (blood pressure)(Assessed in each participant at the clinical follow-up (Day 1).)
- Physical function (sit to stand test)(Assessed in each participant at the clinical follow-up (Day 1).)
- Body composition using bioelectrical impedance technology (InBody770)(Assessed in each participant at the clinical follow-up (Day 1).)
- Albumin excretion rate (urine samples)(Assessed in each participant at the clinical follow-up (Day 1).)
- Heart rate variability (Vagus device)(Assessed in each participant at the clinical follow-up (Day 1).)
- Pulse wave velocity (SphygmoCor)(Assessed in each participant at the clinical follow-up (Day 1).)
- Total daily energy intake (Diet registration)(Assessed in each participant at the clinical follow-up (Day 1).)
- Liver stiffness (FibroScan)(Measured one time during the clinical follow-up study (Day 1).)
- Glycemic variability (CGM)(Assessed in each participant at the clinical follow-up (Day 1).)
- Total daily physical energy expenditure (Sens Motion)(Assessed in each participant at the clinical follow-up (Day 1).)
- Coronary artery calcification score (CT scan)(Assessed in each participant at the clinical follow-up (Day 1).)
- Chronic Kidney Disease (CKD) Stage 3/4/5 (Blood samples)(Assessed in each participant at the clinical follow-up (Day 1).)
研究者
Allan Linneberg
Director, Professor, MD, PhD
Bispebjerg Hospital
